Novo Holdings invests in US$105 million Series C Funding of Alentis Therapeutics

Alentis Therapeutics is a clinical-stage biotech developing breakthrough treatments for organ fibrosis and Claudin-1 (CLDN1) positive tumors
Funding to advance clinical development of two first-in-class anti-CLDN1 antibodies and the platform to engineer CLDN1 antibody drug conjugates (ADC) and bi-specific antibodies
Series C led by Jeito Capital together with Novo Holdings and RA Capital Management
Naveed Siddiqi, Senior Partner at Novo Holdings, joins the Board of Directors

Locations